Veru Reports Positive Phase 2 Clinical Results of VERU-111 in Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome

Go back to Veru Reports Positive Phase 2 Clinical Results of VERU-111 in Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome
(NASDAQ: VERU) Delayed: 7.39 --0 (-0%)
Previous Close $7.39    52 Week High
Open $7.39    52 Week Low
Day High $7.39    P/E N/A 
Day Low $7.39    EPS
Volume 423